Abstract 74P
Background
To study tumor’s genetic phenotype in patients with osteosarcoma and estimate long-term results.
Methods
221 patients with osteosarcoma were included to research. The gender ratio was 133 men, 88 women. The age of patients was from 1 to 35 years. The distribution of patients by localization of tumor was as follows: in 102 patients femoral bone damaged by tumor, in 83 patients – in tibialis, in 16 patients – in fibula, in 11 patients in the radial bone, in 6 patients - in iliac bone, and 5 in the humerus. In all cases, the treatment was performed according to the protocol and treatment standard. The tumor markers (P53; Ki67; BcL2) were studied by the method of immunohistochemistry. The combination of P53 + / Ki67 + / Bcl2 - was considered as a negative combination and the combination of P53 - / Ki67- / Bcl2+ as a positive. Depending on the combination of genetic markers, the survival rate of patients was studied by method of Kaplan-Meier.
Results
The 3 and 5-year survival rates of patients with osteosarcoma who had a positive combination of genetic markers (40.0% and 0%) was lower than patients who had negative P53 - / Ri67 - /Bcl2 + (90.0 ± 2.9% and 40.0 ± 4.2%) (P < 0.05). The 3 and 5-year survival rates without metastasis in adverse gene combinations of P53 + / Ki67 + / Bcl2 + was 70.0 ± 3.4% and 10.0 ± 3.2%, while the positive phenotype was - 90.0 ± 3.4% and 50.0 ± 4.3% (P < 0.05). In the analysis, the 3 and 5 year survival rates without recurrent in the negative phenotype was 60.0 ± 4.9% and 10.0 ±4%, whereas in a positive it was 90.03 ± 3.2% and 50.0 ± 4.2% (P < 0.05).
Conclusions
The research shown that, the forecast was adverse in the positive expression of P53+/Ki67+. The tactics in the treatment of osteosarcoma can be changed by combination of these markers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
N.S. Kamalovich.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
132P - Deciphering aggressive behavior in uterine inflammatory myofibroblastic tumors: Clinicopathological and molecular analysis
Presenter: Nikola Hajkova
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Exploring genomic instability at the single-cell level using a new method for the inference of copy number alterations
Presenter: Lucrezia Patruno
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - SPICE: Probabilistic reconstruction of copy-number evolution in cancer
Presenter: Abigail Bunkum
Session: Cocktail & Poster Display session
Resources:
Abstract
135P - Revealing the third kind of pathway of colorectal cancer developing from laterally spreading tumors
Presenter: Jianshe Yang
Session: Cocktail & Poster Display session
Resources:
Abstract
136P - Investigating the evolutionary and regulatory dynamics of acquired resistance to BTK inhibitors in activated B-cell diffuse large B-cell lymphoma cells
Presenter: Luminita Ruje
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Analysis of master regulatory transcription factors and their associated transcriptomic profiles in SCLC patients
Presenter: Janik Riese
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Rewiring of cis-regulatory and kinase signalling networks in acalabrutinib-resistant ABC DLBCL cells
Presenter: Pavel Artemov
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - MYC subgroups delineate specific transcriptomic landscape and shape response to radiotherapy in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - An unconditionally dynamic culture system for cancer stem cell
Presenter: Ya-Juan Zhu
Session: Cocktail & Poster Display session
Resources:
Abstract